Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$23.47
-2.6%
$32.67
$16.95
$49.50
$1.92B1.771.45 million shs1.18 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$107.89
+3.3%
$101.39
$62.55
$142.79
$40.00B1.623.14 million shs2.43 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$26.32
+0.2%
$27.07
$25.23
$40.37
$148.70B0.6134.94 million shs24.29 million shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-2.61%-8.68%-30.21%-5.21%-23.07%
Moderna, Inc. stock logo
MRNA
Moderna
+3.28%+3.95%+2.33%+6.71%-21.90%
Pfizer Inc. stock logo
PFE
Pfizer
+0.23%+2.45%-3.80%-7.09%-34.05%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.1026 of 5 stars
4.23.00.00.01.92.50.6
Moderna, Inc. stock logo
MRNA
Moderna
3.9718 of 5 stars
3.12.00.04.61.93.30.6
Pfizer Inc. stock logo
PFE
Pfizer
4.995 of 5 stars
3.25.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.38
Hold$41.0074.69% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.24
Hold$126.4917.24% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3338.04% Upside

Current Analyst Ratings

Latest PFE, MRNA, and BEAM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$57.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/11/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/9/2024
Moderna, Inc. stock logo
MRNA
Moderna
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00
4/1/2024
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/28/2024
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$125.00
3/28/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
3/27/2024
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$57.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$377.71M5.07N/AN/A$12.04 per share1.95
Moderna, Inc. stock logo
MRNA
Moderna
$6.85B6.03N/AN/A$36.33 per share2.97
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.55$2.98 per share8.82$15.81 per share1.66

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$132.53M-$1.90N/AN/AN/A-35.09%-15.90%-9.75%5/8/2024 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$4.71B-$12.41N/AN/AN/A-68.84%-10.23%-7.70%5/2/2024 (Confirmed)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3673.119.501.183.62%10.88%4.91%5/1/2024 (Confirmed)

Latest PFE, MRNA, and BEAM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.36N/A+$3.36N/AN/AN/A  
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
2/27/202412/31/2023
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$0.69$1.73+$2.42$1.73$34.16 million$316.20 million
2/22/2024Q4 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$0.78$0.55+$1.33$0.55$2.53 billion$2.80 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.38%+2.57%466.67%15 Years

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
5.89
5.89
Moderna, Inc. stock logo
MRNA
Moderna
0.04
3.42
3.36
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
4.40%
Moderna, Inc. stock logo
MRNA
Moderna
15.20%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
43681.66 million78.07 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600382.88 million324.68 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

PFE, MRNA, and BEAM Headlines

SourceHeadline
6 of the Highest-Yielding S&P 500 Stocks Offer Huge Passive Income6 of the Highest-Yielding S&P 500 Stocks Offer Huge Passive Income
247wallst.com - April 24 at 7:30 AM
The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting WealthThe Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth
investorplace.com - April 24 at 7:25 AM
Pfizer (PFE) Scheduled to Post Quarterly Earnings on WednesdayPfizer (PFE) Scheduled to Post Quarterly Earnings on Wednesday
americanbankingnews.com - April 24 at 1:58 AM
Pfizer’s Emblaveo receives European marketing approval for patients with multidrug-resistant infections and limited treatment optionsPfizer’s Emblaveo receives European marketing approval for patients with multidrug-resistant infections and limited treatment options
pharmabiz.com - April 24 at 12:08 AM
Pfizer confirms end of Boulder R&D operationsPfizer confirms end of Boulder R&D operations
msn.com - April 24 at 12:08 AM
Pfizer Inc. (NYSE:PFE) Shares Bought by South Dakota Investment CouncilPfizer Inc. (NYSE:PFE) Shares Bought by South Dakota Investment Council
marketbeat.com - April 23 at 8:58 PM
Pfizer to shutter Boulder R&D operationsPfizer to shutter Boulder R&D operations
bizwest.com - April 23 at 7:07 PM
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
investorplace.com - April 23 at 3:00 PM
Pfizer (NYSE:PFE) Shares Up 0.5%Pfizer (NYSE:PFE) Shares Up 0.5%
marketbeat.com - April 23 at 2:58 PM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), Pfizer (PFE) and Cardinal Health (CAH)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), Pfizer (PFE) and Cardinal Health (CAH)
markets.businessinsider.com - April 23 at 2:03 PM
Better Buy: Pfizer vs. Viking TherapeuticsBetter Buy: Pfizer vs. Viking Therapeutics
fool.com - April 23 at 9:15 AM
Pfizer vs Moderna battle over COVID vaccine patents begins in UKPfizer vs Moderna battle over COVID vaccine patents begins in UK
finance.yahoo.com - April 23 at 7:37 AM
Pfizer vs Moderna battle over COVID vaccine patents begins in UKPfizer vs Moderna battle over COVID vaccine patents begins in UK
reuters.com - April 23 at 7:21 AM
New York State Common Retirement Fund Has $281.24 Million Position in Pfizer Inc. (NYSE:PFE)New York State Common Retirement Fund Has $281.24 Million Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 22 at 9:33 PM
Pfizer (PFE) Rises Higher Than Market: Key FactsPfizer (PFE) Rises Higher Than Market: Key Facts
zacks.com - April 22 at 6:51 PM
3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years
investorplace.com - April 22 at 5:44 PM
EC approval for Pfizer’s Emblaveo in multidrug-resistant infectionsEC approval for Pfizer’s Emblaveo in multidrug-resistant infections
thepharmaletter.com - April 22 at 3:24 PM
Pfizers Emblaveo Gets EU Marketing Authorization For Serious Infectious DiseasePfizer's Emblaveo Gets EU Marketing Authorization For Serious Infectious Disease
markets.businessinsider.com - April 22 at 3:24 PM
EU regulators approve Pfizer antibiotic EmblaveoEU regulators approve Pfizer antibiotic Emblaveo
seekingalpha.com - April 22 at 3:24 PM
Pfizer (NYSE:PFE) Stock Price Up 1.1%Pfizer (NYSE:PFE) Stock Price Up 1.1%
marketbeat.com - April 22 at 1:55 PM
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment OptionsEuropean Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
finance.yahoo.com - April 22 at 8:35 AM
European Commission Approves Pfizers EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment OptionsEuropean Commission Approves Pfizer's EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
businesswire.com - April 22 at 8:08 AM
Brendel Financial Advisors LLC Buys New Position in Pfizer Inc. (NYSE:PFE)Brendel Financial Advisors LLC Buys New Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 21 at 6:22 PM
Pfizer (NYSE:PFE) Trading 0.9% Higher Pfizer (NYSE:PFE) Trading 0.9% Higher
americanbankingnews.com - April 21 at 3:56 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Beam Therapeutics logo

Beam Therapeutics

NASDAQ:BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.